Botulinum Toxin: Mechanisms of Action

Botulinum toxin (BT) has been perceived as a lethal threat for many centuries. In the early 1980s, this perception completely changed when BT's therapeutic potential suddenly became apparent. We wish to give an overview over BT's mechanisms of action relevant for understanding its therapeutic use. BT's molecular mode of action includes extracellular binding to glycoprotein structures on cholinergic nerve terminals and intracellular blockade of the acetylcholine secretion. BT affects the spinal stretch reflex by blockade of intrafusal muscle fibres with consecutive reduction of Ia/II afferent signals and muscle tone without affecting muscle strength (reflex inhibition). This mechanism allows for antidystonic effects not only caused by target muscle paresis. BT also blocks efferent autonomic fibres to smooth muscles and to exocrine glands. Direct central nervous system effects are not observed, since BT does not cross the blood-brain barrier and since it is inactivated during its retrograde axonal transport. Indirect central nervous system effects include reflex inhibition, normalisation of reciprocal inhibition, intracortical inhibition and somatosensory evoked potentials. Reduction of formalin-induced pain suggests direct analgesic BT effects possibly mediated by blockade of substance P, glutamate and calcitonin gene-related peptide.

[1]  H. Wiegand,et al.  Effects of type a botulinum toxin on the cholinergic transmission at spinal renshaw cells and on the inhibitory action at ia inhibitory interneurones , 1977, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  H. Wellhöner,et al.  125I-Labelled botulinum a neurotoxin: Pharmacokinetics in cats after intramuscular injection , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  D. Dressler,et al.  Autonomic Side Effects of Botulinum Toxin Type B Treatment of Cervical Dystonia and Hyperhidrosis , 2002, European Neurology.

[4]  D. Dressler,et al.  Neuronavigation and neuroanatomy , 2002, Journal of neurology, neurosurgery, and psychiatry.

[5]  D. Ranoux,et al.  Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia , 2002, Journal of neurology, neurosurgery, and psychiatry.

[6]  I. Gibbins,et al.  Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. , 2001, American journal of physiology. Heart and circulatory physiology.

[7]  K. Shimizu,et al.  [Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles]. , 2000, Nippon Ganka Gakkai zasshi.

[8]  K. Shimizu,et al.  Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. , 2001, Japanese journal of ophthalmology.

[9]  A. Berardelli,et al.  Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia , 2000, Annals of neurology.

[10]  K. Foster,et al.  Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. , 2000, Biochemical pharmacology.

[11]  K. Foster,et al.  Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. , 2000, Toxicon : official journal of the International Society on Toxinology.

[12]  J. Rothwell,et al.  Electromyographic Quantification of the Paralysing Effect of Botulinum Toxin in the Sternocleidomastoid Muscle , 2000, European Neurology.

[13]  W. Maixner,et al.  Opposite modulation of capsaicin-evoked substance P release by glutamate receptors , 1999, Neurochemistry International.

[14]  J. Dolly,et al.  Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Berardelli,et al.  Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor , 1998, Muscle & nerve.

[16]  T. Südhof,et al.  Mechanics of membrane fusion , 1998, Nature Structural Biology.

[17]  N. Kohara,et al.  Muscle afferent block for the treatment of oromandibular dystonia , 1998, Movement disorders : official journal of the Movement Disorder Society.

[18]  C D Marsden,et al.  Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. , 1997, Brain : a journal of neurology.

[19]  K. Arimura,et al.  Extrafusal and intrafusal muscle effects in experimental botulinum toxin‐A injection , 1996, Muscle & nerve.

[20]  A. Berardelli,et al.  Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. , 1995, Brain : a journal of neurology.

[21]  H. Shibasaki,et al.  Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp , 1995, Muscle & nerve.

[22]  A. Pastor,et al.  Botulinum neurotoxin alters the discharge characteristics of abducens motoneurons in the alert cat. , 1994, Journal of neurophysiology.

[23]  Thomas C. Südhof,et al.  Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 , 1993, Nature.

[24]  P. Errico,et al.  Botulinum A toxin effects on rat jaw muscle spindles. , 1993, Acta oto-laryngologica.

[25]  M. Verhage,et al.  Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. , 1992, The Journal of biological chemistry.

[26]  P. Girlanda,et al.  Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[27]  C. Shone,et al.  Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. , 1992, European journal of biochemistry.

[28]  D. Truong Botulinum Toxin Therapy , 1991, The Western journal of medicine.

[29]  M. Hallett,et al.  24 – The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin , 1990 .

[30]  Michael J. Aminoff,et al.  Neuromuscular effects distant from the site of botulinum neurotoxin injection , 1988, Neurology.

[31]  C. L. Warner,et al.  Distant effects of local injection of botulinum toxin , 1987, Muscle & nerve.

[32]  R. Tanaka,et al.  TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids , 1986, FEBS letters.

[33]  E. Buckley,et al.  Botulinum toxin for blepharospasm: single-fiber EMG studies , 1986, Neurology.